test

Developmental Therapeutics

Hari Anant Deshpande MD

Associate Professor of Medicine (Medical Oncology) and Assistant Professor of Surgery (Otolaryngology) and Assistant Clinical Professor of Nursing

Clinical Interests

Head and neck cancer; Genitourinary (GU) cancers; sarcomas; thyroid cancer.


Board Certifications

1998
Hematology (Internal Medicine), Board Certified
1995
Internal Medicine, Board Certified
1999
Medical Oncology, Board Certified

Patient Care Locations

hari_deshpandefaculty-clinicsfalsetruetrue6truefalsefalse

Clinical Trials

ConditionsStudy Title
Head and Neck Cancer, Larynx, and Lip, Oral Cavity and PharynxA Phase III Randomized Trial of Chemotherapy with or without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer (ECOG E1305)
Head and Neck Cancer, Larynx, and Lip, Oral Cavity and PharynxRTOG 0920: A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer {CIRB}
LungA Phase 1b Open-label Study to Evaluate the Safety and Tolerability of MEDI4736 in Combination with Tremelimumab in Subjects With Advanced Non-Small Cell Lung Cancer
RTOG 1216: Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered With Concurrent Cisplatin Versus Docetaxel Versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck {CIRB}
Brain and Nervous System and Other Respiratory and Intrathoracic OrgansA randomised, double-blind, placebo-controlled, phase III study to evaluate the efficacy and safety of afatinib (BIBW 2992) as adjuvant therapy after chemo-radiotherapy in primary unresected patients with stage III, IVa, or IVb loco-regionally advanced head and neck squamous cell carcinoma

More Clinical Trials...

Edit Profile